Study of Met34Thr variant in nonsyndromic hearing loss in four Portuguese families

Mariana Dóriaa,*, Susana Fernandesb,c, Carla Pinto Mouraa,c,d

aFaculty of Medicine, University of Porto, Porto, Portugal
bDepartment of Human Genetics, Faculty of Medicine, University of Porto/São João Hospital Center, Porto, Portugal
cInstitute for Research and Innovation in Health/Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal
dDepartment of Otorhinolaryngology and Department of Human Genetics, São João Hospital Center, Porto, Portugal

ABSTRACT

Objective: The purpose of this work was to characterize the Met34Thr variant in a group of patients with nonsyndromic hearing loss, in order to establish a genotype-phenotype correlation.

Methods: 13 cases from 4 unrelated Portuguese families were selected, in which one or more hearing-impaired members had Met34Thr variant.

Results: Met34Thr variant was identified in 11/13 cases. Two cases have an additional mutation – Val153Ile and 35delG. Hearing loss was mild in 2 patients (Met34Thr/Val153Ile; Met34Thr/Met34Thr), moderate in 3 (Met34Thr/WT; Met34Thr/35delG; Met34Thr/Met34Thr), severe in 2 (2 Met34Thr/WT) and profound in 1 (Met34Thr/WT). Three individuals with Met34Thr had normal hearing thresholds.

Conclusion: The present data corroborate the hypothesis that the Met34Thr variant is associated with mild-to-severe forms of deafness and that this variant seems to segregate with a dominant hearing loss with incomplete penetrance and a variable expression of the phenotype. However, other factors are likely to also have a pathologic effect.
The purpose of this work is to characterize the Met34Thr variant in a group of patients with NSHL, in order to establish a genotype-phenotype correlation.

Materials and methods

Patients

All patients were followed in the Clinic of “Hereditary hearing loss” from 2011 till 2014, presenting mild to profound NSHL, assessed by auditory brainstem response tests (ABR) or pure tone audiometry (PTA) and have been studied for GJB2 mutations. To each patient, a complete medical history has been collected to determine the age of onset and deafness evolution, family and patient’s past history; causes of acquired deafness, as infections, surgeries, neonatal diseases and trauma, were excluded. None of them reported a relevant history of otological disease or exposure to ototoxic drugs. Syndromic hearing loss was excluded based on physical examination and complementary diagnostic tests, such as temporal bone computer tomography, and when indicated, ear magnetic resonance imaging, renal ecography and/or intravenous urography. Audiological evaluation of NSHL was performed according to GenDeaf study group recommendations. Air conduction thresholds were measured for 250, 500, 1000, 2000, 4000 and 8000 frequencies. The degree of NSHL was classified by the PTA applied to the better ear at 500, 1000, 2000 and 4000 Hz. Normal hearing is characterized by a PTA-20 dB, mild NSHL 20-40 dB, moderate NSHL 41-70 dB, severe NSHL 71-95 dB and NSHL is classified as profound when PTA>95 dB.

To this study, 13 cases were selected from 4 unrelated Portuguese families, in which one or more hearing-impaired members had Met34Thr variant (homozygous, heterozygous or compound heterozygous).

Genetic analysis

After obtaining informed consent, DNA was extracted from peripheral blood samples, according to standard protocols. DNA samples were amplified by PCR (Polymerase Chain Reaction), using specific primers for GJB2 gene exon 2. The Taq DNA polymerase used was from Thermo Scientific. After purification with AmpureXP® to remove the contaminants, the PCR products were sequenced using the forward primer and analysed on an automated sequencer (ABI 3500, Applied Biosystems®). The reference sequence used to analyse the results was NG_008358.

Large deletions/duplications screening was done by MLPA (Multiplex Ligation-dependent probe amplification) technique using the SALSA MLPA probemix P163-D1 GJB-WFS1 protocol. The analysis of the amplified products was also performed on ABI 3500® technique using the SALSA MLPA probemix P163-D1 GJB-WFS1 protocol. The analysis of the amplified products was also performed on ABI 3500® and the results were analysed with GeneMapper® software. Met34Thr variant is referred in this kit as 101 T>C. Other mutations, like IVS1+1G>A mutation on intron 1, GJB2 exon 1 at position 118-119 and a region in upstream GJB2, 18 nucleotides before exon 1, among others, were also analysed with MLPA.

Results

In this study, 13 cases from 4 unrelated families were selected, in which one or more hearing-impaired members had Met34Thr variant. The families’ genograms with the individuals’ genotype and the phenotype are presented in Figure 1.

Syndromic hearing loss was evaluated for all individuals. The case I-1 from family 1 (Fig. 1) presented a pre-auricular pit but other organs lesions (middle ear, kidney or heart) were excluded using complementary diagnostic tests. None of the individuals complained of dizziness, tinnitus or had barotrauma or relevant history of otological disease. History of consanguinity among the parents was also excluded.

The Met34Thr variant was identified in 11/13 individuals, either as heterozygous or homozygous. Two cases have an additional mutation – Val153Ile and 35delG – (compound heterozygosity) presenting bilateral mild to moderate NSHL.

The audiometric features of the four families reported here revealed that NSHL was found in 8 subjects (Fig. 2). The most compromised frequencies were in the range of 2000-8000Hz, which resulted in a sloping type audiogram configuration. Only one individual (family 2: I-1) reported noise exposure in his workplace, which could explain, at least in part, the worsening found in high frequencies.

Mild NSHL was diagnosed in 2 patients (Met34Thr/Val153Ile; Met34Thr/Met34Thr), 3 moderate NSHL (Met34Thr/WT; Met34Thr/35delG; Met34Thr/Met34Thr), 2 severe NSHL (2 Met34Thr/WT) and 1 profound NSHL (Met34Thr/WT), as it is shown in Table 1. Three individuals with Met34Thr variant had normal hearing thresholds (Fig. 1 - 3 cases: family 2: I-2 and II-2 and family 4: I-1).

Discussion

The presented data corroborate that Met34Thr variant is associated with mild-to-severe forms of deafness. Furthermore, the genogram analysis indicates that Met34Thr might segregate with an autosomal dominant inheritance with incomplete penetrance and variable expression of the phenotype, as described previously in the literature. Recent ideas suggested that this variability can be explained by other factors, as regulatory functions or post transcriptional modifications.

In this study, 73% (8/11) of patients with Met34Thr present NSHL, which point to a pathogenic nature. All individuals have at least one parent with the Met34Thr variant and even those who inherited only one abnormal allele (heterozygous to Met34Thr) presented NSHL, suggesting an autosomal dominant pattern of inheritance. In fact, dominant inheritance has already been described for Met34Thr in 1997, when

Table 1

<table>
<thead>
<tr>
<th>Nr.</th>
<th>Case</th>
<th>Age (yo)</th>
<th>Age of diagnosis (yo)</th>
<th>NSHL</th>
<th>Mutation</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>I-1</td>
<td>53</td>
<td>7</td>
<td>Bilateral severe; Profound to &gt;8 KHz</td>
<td>Met34Thr/WT</td>
<td>Prosthesis</td>
</tr>
<tr>
<td></td>
<td>I-2</td>
<td>53</td>
<td>–</td>
<td>Normal audition</td>
<td>WT/WT</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>25</td>
<td>16</td>
<td>Bilateral moderate</td>
<td>Met34Thr/WT</td>
<td>Prosthesis</td>
</tr>
<tr>
<td>2</td>
<td>I-1</td>
<td>50</td>
<td>4</td>
<td>RE mild and LE moderate</td>
<td>Met34Thr/Val153Ile</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>I-2</td>
<td>48</td>
<td>–</td>
<td>Normal audition</td>
<td>Met34Thr/WT</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>17</td>
<td>10</td>
<td>Bilateral mild</td>
<td>Met34Thr/Met34Thr</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>II-2</td>
<td>14</td>
<td>–</td>
<td>Normal audition</td>
<td>Met34Thr/WT</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>I-1</td>
<td>39</td>
<td>–</td>
<td>Normal audition</td>
<td>WT/WT</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>I-2</td>
<td>38</td>
<td>10</td>
<td>Bilateral moderate</td>
<td>Met34Thr/35delG</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>2</td>
<td>UNHS</td>
<td>Bilateral profound</td>
<td>Met34Thr/WT</td>
<td>Cochlear implant</td>
</tr>
<tr>
<td>4</td>
<td>I-1</td>
<td>33</td>
<td>–</td>
<td>Normal audition</td>
<td>Met34Thr/WT</td>
<td>Prosthesis</td>
</tr>
<tr>
<td></td>
<td>I-2</td>
<td>33</td>
<td>7</td>
<td>Bilateral severe</td>
<td>Met34Thr/WT</td>
<td>Prosthesis</td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>9</td>
<td>8</td>
<td>Bilateral moderate</td>
<td>Met34Thr/Met34Thr</td>
<td>–</td>
</tr>
</tbody>
</table>
Kelsell et al. reported a case of two sisters with profound NSHL and Met34Thr allele heterozygosity. Nevertheless, later on, a second mutation in GJB2 gene was identified, which segregated with hearing loss, causing doubts on this autosomal dominant trait. Subsequently, the association of Met34Thr in homozygosity or Met34Thr in trans with 35delG, Val95Met and Arg184Trp with mild to moderate NSHL pointed to a recessive pattern of inheritance. This interpretation was later questioned due to the frequent findings of normal hearing in compound heterozygous with 35delG. Cases of individuals with this variant and normal audition led to the assumption that this variant could be a normal variant or has an incomplete penetrance.

More recently, investigations studying multiple variables of gene function supported the hypothesis that Met34Thr is a pathogenic variant associated with NSHL by showing that, despite Cx26-Met34Thr protein being correctly synthesized and targeted to the plasma membrane, it is unable to form functional efficient intercellular channels. These studies corroborate the hypothesis here presented that Met34Thr is a pathogenic variant associated with NSHL.

In the present study, we found 3 cases presenting Met34Thr variant without audiometric evidence of NSHL (Fig. 1 - family 2: I-2 and II-2 and family 4: I-1), which corroborates the hypothesis of incomplete penetrance described by Snoeckx et al. and Pollak et al., as the genotype is present but the phenotype is not observable. According to estimates from Pollak et al., the penetrance of Met34Thr/35delG genotypes relative to the 35delG/35delG genotypes is approximately 1/10. The absence of the phenotype in individual II-2 (14 y.o.) from family 2 might also be explained by later onset of the NSHL. The follow up of...
this case for a long period could be helpful to determine whether she develops NSHL or not. Reports of a ‘window’ of normal hearing before the diagnosis have been previously described in the literature.22 Indeed, in this work, the age of diagnosis was different among all the individuals (see Table 1) and only one case reported neonatal diagnosis.

Our data also support a phenotype variable expression, because despite these 8 cases showed segregation with NSHL, they all presented with different degrees of severity of the phenotype, even within the same family. For instance, individuals from family 1 (Fig. 1- I-1 and II-1), both Met34Thr heterozygous (Met34Thr/WT), presented different degrees of phenotype severity (I-1 with bilateral severe NSHL and II-1 with bilateral moderate NSHL). This hypothesis has already been described in other studies, suggesting that the effect of GJB2 mutations (including Met34Thr) can be substantially modified by still unknown genetic or environmental factors.4,23,24 It can often be masked by these modifiers.25 Bicego et al. suggested that a 10 bp deletion in the 5‘-untranslated regions of the GJB2 gene could alter the expression levels of the Met34Thr allele in vivo, accounting for the phenotype variability in Met34Thr heterozygous.12,26

It has been suggested that Met34Thr is associated with less severe degrees of NSHL compared with other GJB2 mutations,4,10,12 especially if presented in homozygosity.4,23,25 Our data show that homozygous usually present NSHL ranging from mild to moderate (Fig. 1 family 2: II-1 and family 4: II-1). The only case with profound NSHL (Fig. 1 family 3: II-1) was heterozygous. The case with the genotype Met34Thr/35delG presented moderate NSHL, corroborating previous studies.4,26

The fact that Met34Thr segregates with milder levels of NSHL could explain the lower frequency of Met34Thr found in patients with NSHL compared with 35delG, as persons with milder NSHL, unless involved in family studies, are less likely to undergo genetic testing.4 Another confounding factor is the range of frequencies used to assess NSHL. Previous studies only analyzed the 500, 1000 and 2000 Hz frequencies, while recent ones suggest that the assessment of a wider range of frequencies may help uncover milder cases of NSHL associated with Met34Thr.18,20 In the present work, we also considered the frequency of 4000 Hz to help overcoming this problem.

A report in general population from UK demonstrated that Met-34Thr carriers presented worse hearing thresholds at extra-high frequencies – 16 KHz.13 These frequencies are not usually assessed in clinical or not-for-profit sectors.

In conclusion, our clinical data indicate that Met34Thr variation might be pathogenic and may segregate with a dominant transmission with incomplete penetrance and variable phenotype expression. Other modifying factors are likely to also have a role in the variability of phenotype severity. High frequencies loss is frequently associated with this variant. Therefore, the possible progressive late onset hearing impairment requires a long follow-up of these individuals, with the assessment of 8-20 KHz.

Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.